All In Biotech

NDA 205436 · Cubist Pharms LLC

Sivextro

Tedizolid Phosphate · Intravenous

Priority review

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jun 20, 2014

Approved uses

4

Original approval plus efficacy supplements

Registered trials

35

7 Phase 3, 2 recruiting

FAERS reports

803

528 serious, 51 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 27, 2026.

SIVEXTRO is an oxazolidinone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible microorganisms in adult and pediatric patients (at least 26 weeks gestational age and weighing at least 1 kg) ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 1.1 Acute Bacterial Skin and Skin Structure Infections SIVEXTRO ® is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus Group (including Streptococcus anginosus , Streptococcus intermedius , and Streptococcus constellatus ), and Enterococcus faecalis , in adult and pediatric patients (at least 26 weeks gestational age and weighing at least 1 kg). 1.2 Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric...

Mechanism: Tedizolid is an antibacterial drug [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SIVEXTRO · TEDIZOLID PHOSPHATE 200MG/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tedizolid" as an intervention, any sponsor and status, largest first.

All 35 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use110
  • product use in unapproved indication88
  • thrombocytopenia62
  • anaemia51
  • nausea45
  • no adverse event43
  • drug ineffective36
  • pancytopenia34
  • product availability issue33
  • product dose omission issue32
  • diarrhoea27
  • rash25

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201410
201539
201634
201741
201855
2019108
202083
202173
202262
2023109
202469
202572
202648

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sivextro* (Tedizolid Phosphate)

2024 spending

$16.5M

Beneficiaries

505

1,534 claims

Per beneficiary

$32,723

$421.26 per unit

View as table
YearSpending
2020$12,709,902
2021$12,823,638
2022$17,779,287
2023$11,498,831
2024$16,525,191

Part B: Sivextro (Tedizolid Phosphate) · HCPCS J3090

2024 spending

$52K

Beneficiaries

28

149 claims

Per beneficiary

$1,841

2024 ASP limit $1.80 per unit

View as table
YearSpending
2020$80,337
2021$43,542
2022$72,395
2023$53,138
2024$51,551

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 43 on PubMed

Sponsor: Cubist Pharms LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.